Composition for improving CAR-T cell function and preparation method and application thereof
By preparing a composition of avalomat/polyanthimethrin eutectics, coenzyme Q10, valproic acid and other components, using porous microsphere carriers, the problems of complex and high cost of CAR-T cell culture medium are solved, and the The anti-tumor activity and reproductive ability of CAR-T cells achieve high stability and low cost effects.
Patent Information
- Application Number
- CN202411138099.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-06-03
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-26
AI Technical Summary
The existing CAR-T cell culture media have problems such as complex components, high cost, easy cell depletion and poor killing ability, which affects the anti-tumor activity of CAR-T cells.
By preparing a composition of avalomat/polyanthimethrin eutectics, coenzyme Q10, valproic acid and other components, using porous microspheres as carriers, these components are adsorbed and fixed by silane coupling agent and tannin acid using porous microspheres as carriers. , a slow-release composition is formed and added to the culture medium of CAR-T cells to improve cell activity and reproductive capacity.
Effectively inhibit the activity of the cholesterol esterase ACAT1 in the T cell metabolic pathway, reduce oxidative damage and inflammatory response, improve the anti-tumor activity of CAR-T cells, has high stability and low cost, and has broad application prospects.
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical technology, and in particular to a composition for improving the function of CAR-T cells, and a preparation method and application thereof. Background Art
[0002] Immunotherapy is a treatment method that artificially intervenes in the body's immune function to treat the disease when the body is in an abnormal immune state. Other clinical tumor treatment methods, such as chemotherapy, radiotherapy, and targeted therapy, target tumor cells and tissues, while immunotherapy is completely different. Immunotherapy targets the patient's own immune system. The application of immunotherapy requires immune cells, and commonly used immune cells are T cells.
[0003] In clinical trials, researchers have been able to transform T cells through genetic engineering technology, shaping them from "warriors" to "super warriors." The lentivirus containing chimeric antigen receptors that can recognize tumor cells and activate T cells is transfected into T cells, and finally a chimeric antigen receptor T cell (CAR-T) that can specifically recognize tumor cells in the patient's body and release a variety of cytokines through the immune action of the immune system is obtained. CAR-T cells can efficiently kill tumor cells and achieve the purpose of treating diseases. However, tumor cells can inhibit the anti-tumor activity of CAR-T cells through various mechanisms, thereby escaping the attack of the immune system. In clinical practice, tumors can be treated by increasing the activity of CAR-T cells. In order to obtain a large number of CAR-T cells in clinical practice, in vitro culture and in vitro expansion are usually required. The type of culture medium used in the culture, the culture process, etc. will affect the performance of the CAR-T cells finally obtained. At present, the commonly used CAR-T culture medium has problems such as complex composition, high culture cost, easy exhaustion of cells, and poor killing ability. Summary of the invention
[0004] The purpose of the present invention is to propose a composition for improving the function of CAR-T cells, and a preparation method and application thereof, which improves the anti-tumor activity of CAR-T cells by inhibiting the activity of cholesterol esterase ACAT1 in the T cell metabolic pathway and reducing oxidative damage and inflammatory response. At the same time, it has high sustained-release and stability. By adding it to the culture medium of CAR-T cells, it greatly promotes the activity and reproduction ability of the cells. The addition amount is low, the cost is low, and it has broad application prospects.
[0005] The technical solution of the present invention is achieved in this way:
[0006] The present invention provides a method for preparing a composition for improving the function of CAR-T cells. A porous microsphere is prepared by a sol-gel reaction. After the surface is modified with a silane coupling agent and tannic acid, avasimib / polyantigen acetylcholine cocrystal, coenzyme Q10, and valproic acid are adsorbed, washed, and dried to obtain the composition for improving the function of CAR-T cells.
[0007] As a further improvement of the present invention, the following steps are included:
[0008] S1. Preparation of avasimibe / polyantigen A cocrystal: dissolving avasimibe in DMSO solvent to obtain solution A; dissolving polyantigen A in water to obtain solution B; mixing solution A and solution B evenly, evaporating the solvent in an open manner, filtering, washing, drying, and ball milling to obtain avasimibe / polyantigen A cocrystal;
[0009] S2. Preparation of porous microspheres: dissolving alkyl orthosilicate in ethanol, dropping into an aqueous solution containing ammonia and a porogen, stirring to react, centrifuging, washing, and drying to obtain porous microspheres;
[0010] S3. Preparation of modified microspheres: adding the porous microspheres obtained in step S2 to ethanol, adding a composite silane coupling agent and tannic acid, heating and stirring the reaction, centrifuging, washing, and drying to obtain modified microspheres;
[0011] S4. Preparation of additives: mixing coenzyme Q10 and valproic acid to obtain an additive;
[0012] S5. Preparation of a composition for improving the function of CAR-T cells: add the modified microspheres prepared in step S3 into water, add the avasimibe / polyantigen methyl cocrystal prepared in step S1 and the additive prepared in step S4, stir and mix evenly, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0013] As a further improvement of the present invention, the solid-liquid ratio of avasimibe and DMSO solvent in step S1 is 3-4:100 g / mL, the solid-liquid ratio of polyantibiotic A and water is 7-10:100 g / mL, the mass ratio of solution A and solution B is 10:25-32, and the ball milling time is 1-3 h.
[0014] As a further improvement of the present invention, the alkyl orthosilicate in step S2 is methyl orthosilicate or ethyl orthosilicate, the mass ratio of the alkyl orthosilicate and the aqueous solution containing ammonia water and a porogen is 7-10:100, and in the aqueous solution containing ammonia water and a porogen, the mass ratio of ammonia water, the porogen and water is 5-7:2-3:30-50, the porogen is hexadecyltrimethylammonium chloride or hexadecyldimethylbenzylammonium chloride, and the stirring reaction time is 12-15h.
[0015] As a further improvement of the present invention, in step S3, the mass ratio of the porous microspheres, the composite silane coupling agent and tannic acid is 15-20:4-7:2-4, the composite silane coupling agent is KH580 and KH550, the mass ratio is 4-7:2-4, the temperature of the heating and stirring reaction is 40-50°C, and the time is 2-4h.
[0016] As a further improvement of the present invention, the mass ratio of coenzyme Q10 to valproic acid in step S4 is 5-7:1-2.
[0017] As a further improvement of the present invention, the mass ratio of the modified microspheres, avasimibe / polyantibiotic cocrystal, and additives in step S5 is 50:0.5-1:1-2.
[0018] As a further improvement of the present invention, the present invention specifically comprises the following steps:
[0019] S1. Preparation of Avasimibe / Polyantigen A cocrystal: Dissolve Avasimibe in DMSO solvent to obtain solution A, wherein the solid-liquid ratio of Avasimibe to DMSO solvent is 3-4:100 g / mL; Dissolve Polyantigen A in water to obtain solution B, wherein the solid-liquid ratio of Polyantigen A to water is 7-10:100 g / mL; Mix 10 parts by weight of solution A and 25-32 parts by weight of solution B, evaporate the solvent in an open manner, filter, wash, dry, and ball-mill for 1-3 hours to obtain Avasimibe / Polyantigen A cocrystal;
[0020] S2. Preparation of porous microspheres: 7-10 parts by weight of alkyl orthosilicate was dissolved in ethanol, dropped into 100 parts by weight of an aqueous solution containing ammonia and a porogen, stirred for 12-15h, centrifuged, washed, and dried to obtain porous microspheres;
[0021] In the aqueous solution containing ammonia water and a porogen, the mass ratio of ammonia water, the porogen and water is 5-7:2-3:30-50;
[0022] S3. Preparation of modified microspheres: 15-20 parts by weight of the porous microspheres prepared in step S2 were added to ethanol, 4-7 parts by weight of a composite silane coupling agent and 2-4 parts by weight of tannic acid were added, heated to 40-50 ° C, stirred for 2-4h, centrifuged, washed, and dried to obtain modified microspheres;
[0023] The composite silane coupling agent is KH580 and KH550, with a mass ratio of 4-7:2-4;
[0024] S4. Preparation of additives: 5-7 parts by weight of coenzyme Q10 and 1-2 parts by weight of valproic acid are mixed to obtain an additive;
[0025] S5. Preparation of a composition for improving the function of CAR-T cells: add 50 parts by weight of the modified microspheres prepared in step S3 to 200 parts by weight of water, add 0.5-1 parts by weight of the avasimibe / polyantigen methyl cocrystal prepared in step S1 and 1-2 parts by weight of the additive prepared in step S4, stir and mix evenly, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0026] The present invention further protects a composition for improving the function of CAR-T cells obtained by the above-mentioned preparation method.
[0027] The present invention further protects the use of the above-mentioned composition for improving the function of CAR-T cells, which is added to the CAR-T cell culture medium to improve the viability, proliferation ability and anti-tumor function of CAR-T cells.
[0028] The present invention has the following beneficial effects:
[0029] Avasimibe, a small molecule inhibitor of ACAT1 in the present invention, can greatly improve the anti-tumor function of CD8+T cells (also known as killer T cells), so that the level of free cholesterol on the killer T cell membrane is increased, thereby making the T cell tumor antigen immune response more efficient. However, avasimibe has poor water solubility and low molecular bioavailability, which prevents it from exerting a good drug effect. Polyantigen A is a polysaccharide substance, the main component of which is α-mannan peptide, which can activate the phagocytic function of macrophages, activate lymphocytes, improve the immune function of CD3 and CD4, and has good water solubility. The present invention prepares avasimibe / polyantigen A cocrystal, and combines the two with a fixed stoichiometric ratio through non-covalent bonds such as hydrogen bonds, van der Waals forces, π-π stacking, and halogen bonds to form a crystal, which greatly improves the water solubility and bioavailability of avasimibe, and at the same time, improves the stability of the drug.
[0030] The present invention prepares micron-sized porous SiO 2 The microspheres are modified with surface silane coupling agents (silane coupling agents KH580 and KH550) and tannic acid, and have abundant active groups such as thiol, amino, hydroxyl and carboxyl groups. They can bind to coenzyme Q10, valproic acid, nivolumab OPDIVO and avasimib / polyclonal antibody cocrystals through hydrogen bonds and van der Waals forces, and are fixed on the surface and pores of the microspheres, achieving the effects of sustained and controlled release and improving the stability of drugs and proteins.
[0031] Among them, valproic acid is a histone deacetylase inhibitor that can improve mitochondrial membrane potential, inhibit cytochrome C release and promote mitochondrial ATP synthesis, and reduce cell damage induced by impaired mitochondrial respiration in CAR-T cells. Coenzyme Q10 can reduce mitochondrial oxidative stress (OS) induced by free radicals and protect the cell membrane outside the mitochondria, reduce CAR-T cell immune dysfunction, and play a role in protecting and improving cell activity. The two have a synergistic effect.
[0032] The composition for improving the function of CAR-T cells prepared by the present invention can improve the anti-tumor activity of CAR-T cells by inhibiting the activity of cholesterol esterase ACAT1 in the T cell metabolic pathway and reducing oxidative damage and inflammatory response. At the same time, it has high sustained-release and stability. By adding it to the culture medium of CAR-T cells, it greatly promotes the activity and reproduction ability of the cells. The addition amount is low, the cost is low, and it has broad application prospects. DETAILED DESCRIPTION
[0033] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0034] Example 1
[0035] This embodiment provides a method for preparing a composition for improving the function of CAR-T cells, which specifically comprises the following steps:
[0036] S1. Preparation of Avasimibe / Polyantigen A cocrystal: 3 g of Avasimibe was dissolved in 100 mL of DMSO solvent to obtain solution A, 7 g of Polyantigen A was dissolved in 100 mL of water to obtain solution B, 100 g of solution A and 250 g of solution B were stirred and mixed for 10 min, the solvent was evaporated in an open manner, filtered, washed, dried, and ball-milled for 1 h to obtain Avasimibe / Polyantigen A cocrystal;
[0037] S2. Preparation of porous microspheres: 7 g of methyl orthosilicate was dissolved in 50 mL of ethanol, and then dropped into 100 g of an aqueous solution containing 25 wt % ammonia and hexadecyltrimethylammonium chloride, and the reaction was stirred for 12 h, centrifuged, washed, and dried to obtain porous microspheres;
[0038] In the aqueous solution containing ammonia water and hexadecyltrimethylammonium chloride, the mass ratio of 25wt% ammonia water, hexadecyltrimethylammonium chloride and water is 5:2:30;
[0039] S3. Preparation of modified microspheres: 15 g of the porous microspheres prepared in step S2 were added to 100 mL of ethanol, 4 g of a composite silane coupling agent and 2 g of tannic acid were added, heated to 40 ° C, stirred for 2 h, centrifuged, washed, and dried to obtain modified microspheres;
[0040] The composite silane coupling agent is KH580 and KH550, with a mass ratio of 4:2;
[0041] S4. Preparation of additives: 5 g of coenzyme Q10 and 1 g of valproic acid were stirred and mixed for 10 min to obtain an additive;
[0042] S5. Preparation of a composition for improving the function of CAR-T cells: add 50 g of the modified microspheres prepared in step S3 to 200 mL of water, add 0.5 g of the avasimibe / polyantigen acetylcholine cocrystal prepared in step S1 and 1 g of the additive prepared in step S4, stir and mix for 20 minutes, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0043] Example 2
[0044] This embodiment provides a method for preparing a composition for improving the function of CAR-T cells, which specifically comprises the following steps:
[0045] S1. Preparation of Avasimibe / Polyantigen A cocrystal: 4 g of Avasimibe was dissolved in 100 mL of DMSO solvent to obtain solution A, 10 g of Polyantigen A was dissolved in 100 mL of water to obtain solution B, 100 g of solution A and 320 g of solution B were stirred and mixed for 10 min, the solvent was evaporated in an open manner, filtered, washed, dried, and ball-milled for 3 h to obtain Avasimibe / Polyantigen A cocrystal;
[0046] S2. Preparation of porous microspheres: 10 g of methyl orthosilicate or ethyl orthosilicate was dissolved in 50 mL of ethanol, and then dropped into 100 g of an aqueous solution containing 25 wt % ammonia and hexadecyl dimethyl benzyl ammonium chloride, and the reaction was stirred for 15 h, centrifuged, washed, and dried to obtain porous microspheres;
[0047] In the aqueous solution containing ammonia water and hexadecyl dimethyl benzyl ammonium chloride, the mass ratio of 25 wt % ammonia water, hexadecyl dimethyl benzyl ammonium chloride and water is 7:3:50;
[0048] S3. Preparation of modified microspheres: 20 g of the porous microspheres prepared in step S2 were added to 100 mL of ethanol, 7 g of a composite silane coupling agent and 4 g of tannic acid were added, heated to 50 ° C, stirred for 4 h, centrifuged, washed, and dried to obtain modified microspheres;
[0049] The composite silane coupling agent is KH580 and KH550, with a mass ratio of 7:4;
[0050] S4. Preparation of additives: 7 g of coenzyme Q10 and 2 g of valproic acid were stirred and mixed for 10 min to obtain an additive;
[0051] S5. Preparation of a composition for improving the function of CAR-T cells: add 50 g of the modified microspheres prepared in step S3 to 200 mL of water, add 1 g of the avasimibe / polyantigen acetylcholine cocrystal prepared in step S1 and 2 g of the additive prepared in step S4, stir and mix for 20 minutes, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0052] Example 3
[0053] This embodiment provides a method for preparing a composition for improving the function of CAR-T cells, which specifically comprises the following steps:
[0054] S1. Preparation of Avasimibe / Polyantimycin A cocrystal: 3.5 g of Avasimibe was dissolved in 100 mL of DMSO solvent to obtain solution A, 8.5 g of Polyantimycin A was dissolved in 100 mL of water to obtain solution B, 100 g of solution A and 300 g of solution B were stirred and mixed for 10 min, the solvent was evaporated in an open manner, filtered, washed, dried, and ball-milled for 2 h to obtain Avasimibe / Polyantimycin A cocrystal;
[0055] S2. Preparation of porous microspheres: 8.5 g of methyl orthosilicate or ethyl orthosilicate was dissolved in 50 mL of ethanol, and then dropped into 100 g of an aqueous solution containing 25 wt % ammonia and hexadecyltrimethylammonium chloride, and the reaction was stirred for 13 h, centrifuged, washed, and dried to obtain porous microspheres;
[0056] In the aqueous solution containing ammonia water and hexadecyltrimethylammonium chloride, the mass ratio of 25wt% ammonia water, hexadecyltrimethylammonium chloride and water is 6:2.5:40;
[0057] S3. Preparation of modified microspheres: 17 g of the porous microspheres prepared in step S2 were added to 100 mL of ethanol, 5.5 g of a composite silane coupling agent and 3 g of tannic acid were added, heated to 45 ° C, stirred for 3 h, centrifuged, washed, and dried to obtain modified microspheres;
[0058] The composite silane coupling agent is KH580 and KH550, with a mass ratio of 5:3;
[0059] S4. Preparation of additives: 6 g of coenzyme Q10 and 1.5 g of valproic acid were stirred and mixed for 10 min to obtain an additive;
[0060] S5. Preparation of a composition for improving the function of CAR-T cells: add 50 g of the modified microspheres prepared in step S3 to 200 mL of water, add 0.7 g of the avasimibe / polyantigen acetylcholine cocrystal prepared in step S1 and 1.5 g of the additive prepared in step S4, stir and mix for 20 minutes, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0061] Example 4
[0062] Compared with Example 3, the difference is that the composite silane coupling agent is a single KH580.
[0063] Example 5
[0064] Compared with Example 3, the difference is that the composite silane coupling agent is a single KH550.
[0065] Comparative Example 1
[0066] Compared with Example 3, the difference is that no composite silane coupling agent is added in step S3.
[0067] The details are as follows:
[0068] S3. Preparation of modified microspheres: 17 g of the porous microspheres prepared in step S2 were added to 100 mL of ethanol, 8.5 g of tannic acid were added, heated to 45° C., stirred for reaction for 3 h, centrifuged, washed, and dried to obtain modified microspheres.
[0069] Comparative Example 2
[0070] Compared with Example 3, the difference is that tannic acid is not added in step S3.
[0071] The details are as follows:
[0072] S3. Preparation of modified microspheres: 17 g of the porous microspheres prepared in step S2 were added to 100 mL of ethanol, 8.5 g of a composite silane coupling agent was added, heated to 45 ° C, stirred for 3 h, centrifuged, washed, and dried to obtain modified microspheres;
[0073] The composite silane coupling agent is KH580 and KH550, and the mass ratio is 5:3.
[0074] Comparative Example 3
[0075] Compared with Example 3, the difference is that coenzyme Q10 is not added in step S4.
[0076] Comparative Example 4
[0077] Compared with Example 3, the difference is that valproic acid is not added in step S4.
[0078] Comparative Example 5
[0079] Compared with Example 3, the difference is that no additive is added in step S5.
[0080] The details are as follows:
[0081] S5. Preparation of a composition for improving the function of CAR-T cells: add 50 g of the modified microspheres prepared in step S3 to 200 mL of water, add 2.2 g of the avasimibe / polyantigen acetylcholine cocrystal prepared in step S1, stir and mix for 20 minutes, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0082] Comparative Example 6
[0083] Compared with Example 3, the difference is that in step S5, the avasimibe / polyantibiotic cocrystal is replaced by avasimibe.
[0084] The details are as follows:
[0085] S5. Preparation of a composition for improving the function of CAR-T cells: Add 50 g of the modified microspheres obtained in step S3 to 200 mL of water, add 0.7 g of avasimibe and 1.5 g of the additive obtained in step S4, stir and mix for 20 minutes, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0086] Comparative Example 7
[0087] Compared with Example 3, the difference is that in step S5, the avasimibe / polyantigen A cocrystal is replaced by polyantigen A.
[0088] The details are as follows:
[0089] S5. Preparation of a composition for improving the function of CAR-T cells: add 50 g of the modified microspheres obtained in step S3 to 200 mL of water, add 0.7 g of polyantigen A and 1.5 g of the additive obtained in step S4, stir and mix for 20 minutes, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0090] Comparative Example 8
[0091] Compared with Example 3, the difference is that no avaimibe / polyantibiotic cocrystal is added in step S5.
[0092] The details are as follows:
[0093] S5. Preparation of a composition for improving the function of CAR-T cells: Add 50 g of the modified microspheres obtained in step S3 to 200 mL of water, add 2.2 g of the additive obtained in step S4, stir and mix for 20 minutes, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
[0094] Comparative Example 9
[0095] Compared with Example 3, the difference is that no modified microspheres are added in step S5.
[0096] The details are as follows:
[0097] S5. Preparation of a composition for improving the function of CAR-T cells: 0.7 g of the avasimibe / polyantigen cocrystal prepared in step S1 and 1.5 g of the additive prepared in step S4 were stirred and mixed for 20 minutes to prepare a composition for improving the function of CAR-T cells.
[0098] Test Example 1
[0099] The composition for improving the function of CAR-T cells prepared in Examples 1-5 and Comparative Examples 1-9 of the present invention was added to a serum-free RPMI 1640 medium at an addition amount of 10 μg / ml to obtain a medium 1. The serum-free RPMI 1640 medium was used as a control group.
[0100] The composition for improving the function of CAR-T cells prepared in Examples 1-5 and Comparative Examples 1-9 of the present invention was added to the AIM medium at an addition amount of 10 μg / ml to obtain medium 2. The AIM medium was used as the control group.
[0101] CD19-CAR lentivirus preparation:
[0102] The CD19-CAR sequence was constructed according to the method of a published patent (CN 107365798 A), and its plasmid was commissioned to GeneWeichi for full gene synthesis.
[0103] Day 1: Take out the CD19-CAR lentiviral vector plasmid from the -80℃ refrigerator and thaw on ice, prepare DNAmix and PEImix reagents, transfer them into nuclease-free EP tubes and incubate at room temperature for 5 minutes, then add the two tubes into the same tube and gently blow to mix, and incubate at room temperature for 30 minutes. Take out the 293T cells and remove the upper culture medium, and slowly add 6.4mL Opti-MEM TM Then slowly drip the DNA-PEI mixture into the culture medium. After gently shaking, place it in a 37℃ carbon dioxide incubator and incubate for 8 hours. Remove the culture medium supernatant containing the DNA-PEI mixture and add 8mL Opti-MEM TM The culture medium was continued for 48 h.
[0104] Day 3: Take out the 293T cells, collect the culture supernatant and transfer it to a 50mL centrifuge tube, place it in a low-temperature ultracentrifuge, and centrifuge it. Use a syringe to filter the supernatant through a 0.45μm filter, transfer it to a new centrifuge tube, centrifuge it, and concentrate the virus liquid. Remove the supernatant, add PBS to resuspend the precipitate according to the required concentration, obtain the concentrated virus liquid, divide it into frozen EP tubes, and store it in a -80℃ refrigerator for later use.
[0105] Isolation, culture and transduction of T cells:
[0106] Fresh blood was collected from healthy volunteers and drawn into blood collection anticoagulant tubes. Whole blood was diluted with an equal volume of PBS and slowly covered on the upper layer of Ficoll-Paque PLUS along the wall of the centrifuge tube. Human peripheral blood mononuclear cells (PBMCs) were separated by density gradient centrifugation. After washing the cells twice, the separated PBMCs were resuspended in AIM medium containing 10% FBS, 1wt% penicillin-streptomycin, 1wt% Glutamax-1 and 100IU / mL IL-2 and incubated at 37°C, 5% CO 2 The cells were cultured in a cell culture incubator, and fresh culture medium was replaced after 3 days. After 6 days of culture, PBMCs were obtained by centrifugation. PBMCs were mixed with magnetic beads conjugated with anti-CD3 and anti-CD28 antibodies at a ratio of 1:1, and the cells were resuspended in 5% FBS to a final concentration of 1×10 8 / mL, at 25°C room temperature, mixed for 30 min, and after incubation, the T cells were counted (cells on day 0) and the number of cells was 10 5 -10 6 / mL and cultured in medium 1 for 1 day.
[0107] Day 2: Observe the cell status, count with a hemocytometer, add virus at an MOI of 2.5, then add recombinant human IL-2 250 U / mL and polybrene 4 μg / mL; record the time of virus addition, collect cells 6 hours after virus addition, centrifuge, and resuspend the cells in fresh medium 2 at a density of 1-2×10 6 / mL.
[0108] Day 3: Observe the cell status. If the cell density is high, add appropriate amount of fluid. The culture medium is medium 2.
[0109] Day 4: Observe the cell status, count with a hemocytometer, and replenish the solution until the cell concentration is about 1-2×10 6 / mL; flow cytometry was used to detect the CD19 positive rate to evaluate the CARs transfection rate. After the infection rate reached more than 70%, the cells were cultured for 3 days.
[0110] Take out 15 μL of the mixed cell suspension by pipetting, mix it with the same volume of AO / PI dye, add 20 μL of the mixture to the sample wells of the counting plate, and use a cell counter to detect the activity and number of live cells of CAR-T cells.
[0111] Calculate relative CAR-T cell viability:
[0112] Relative CAR-T cell viability = number of live cells in the sample group / number of live cells in the control group × 100%
[0113] The cell suspension was cultured for 14 days. The cells were counted again on the 15th day of the experiment to calculate the proliferation rate:
[0114] Proliferation rate = number of viable cells on day 15 / number of viable cells on day 0
[0115] The results are shown in Table 1.
[0116] Table 1
[0117] Group Cell viability (%) Proliferation rate Example 1 175 75 Example 2 177 78 Example 3 181 80 Example 4 163 71 Example 5 160 70 Comparative Example 1 154 68 Comparative Example 2 166 72 Comparative Example 3 160 70 Comparative Example 4 156 68 Comparative Example 5 148 64 Comparative Example 6 162 73 Comparative Example 7 158 71 Comparative Example 8 150 70 Comparative Example 9 173 62
[0118] It can be seen from the above table that the composition for improving the function of CAR-T cells prepared in Examples 1-3 of the present invention can significantly improve the viability of CAR-T cells and improve their proliferation ability.
[0119] After 15 days of culture, the CAR-T cells (effector cells) were centrifuged and resuspended in RPMI 1640 medium (supplemented with 200 IU / mL IL-2) at a cell concentration of 5×10 5 According to the effector-target ratio of 1:1, the target cells (Nalm-6 cells labeled with GFP fluorescence, with a concentration of 5×10 5 50 μL of effector cells were inoculated into 96-well plates, with 3 replicates per group. Incubate at 37°C and 5% CO 2 The cells were cultured in a cell culture incubator for 1 day, centrifuged, and the survival rate of Nalm-6 cells was detected using an ELISA instrument to obtain the killing rate of Nalm-6 cells by CAR-T cells.
[0120] Survival rate (%) = number of Nalm-6 viable cells after culture / number of Nalm-6 viable cells before culture × 100%
[0121] Killing rate (%) = 100% - survival rate
[0122] The results are shown in Table 2.
[0123] Table 2
[0124] Group Kill rate (%) Control group 25.7 Example 1 83.9 Example 2 84.1 Example 3 85.2 Example 4 80.4 Example 5 81.2 Comparative Example 1 78.6 Comparative Example 2 79.3 Comparative Example 3 74.6 Comparative Example 4 75.4 Comparative Example 5 72.2 Comparative Example 6 70.9 Comparative Example 7 72.1 Comparative Example 8 68.6 Comparative Example 9 75.9
[0125] It can be seen from the above table that the composition for improving the function of CAR-T cells prepared in Examples 1-3 of the present invention can significantly improve the killing rate of CAR-T cells against Nalm-6 cells.
[0126] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for preparing a composition for improving CAR-T cell function, characterized in that: Porous microspheres were prepared through a sol-gel reaction. After the surface was modified with a silane coupling agent and tannic acid, avasimib / polyantigen acetylcholine cocrystal, coenzyme Q10, and valproic acid were adsorbed, washed, and dried to obtain a composition that improves the function of CAR-T cells.
2. The preparation method according to claim 1, characterized in that: The following steps are involved: S1. Preparation of avasimibe / polyantigen A cocrystal: dissolving avasimibe in DMSO solvent to obtain solution A; dissolving polyantigen A in water to obtain solution B; mixing solution A and solution B evenly, evaporating the solvent in an open manner, filtering, washing, drying, and ball milling to obtain avasimibe / polyantigen A cocrystal; S2. Preparation of porous microspheres: dissolving alkyl orthosilicate in ethanol, dropping into an aqueous solution containing ammonia and a porogen, stirring to react, centrifuging, washing, and drying to obtain porous microspheres; S3. Preparation of modified microspheres: adding the porous microspheres obtained in step S2 to ethanol, adding a composite silane coupling agent and tannic acid, heating and stirring the reaction, centrifuging, washing, and drying to obtain modified microspheres; S4. Preparation of additives: mixing coenzyme Q10 and valproic acid to obtain an additive; S5. Preparation of a composition for improving the function of CAR-T cells: add the modified microspheres prepared in step S3 into water, add the avasimibe / polyantigen methyl cocrystal prepared in step S1 and the additive prepared in step S4, stir and mix evenly, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
3. The preparation method according to claim 2, characterized in that: In step S1, the solid-liquid ratio of avasimibe and DMSO solvent is 3-4:100 g / mL, the solid-liquid ratio of polyantibiotic A and water is 7-10:100 g / mL, the mass ratio of solution A and solution B is 10:25-32, and the ball milling time is 1-3 h.
4. The preparation method according to claim 2, characterized in that: The alkyl orthosilicate in step S2 is methyl orthosilicate or ethyl orthosilicate, the mass ratio of the alkyl orthosilicate and the aqueous solution containing ammonia and a porogen is 7-10:100, the mass ratio of ammonia, the porogen and water in the aqueous solution containing ammonia and a porogen is 5-7:2-3:30-50, the porogen is hexadecyltrimethylammonium chloride or hexadecyldimethylbenzylammonium chloride, and the stirring reaction time is 12-15h.
5. The preparation method according to claim 2, characterized in that: The mass ratio of the porous microspheres, the composite silane coupling agent and tannic acid in step S3 is 15-20:4-7:2-4, the composite silane coupling agent is KH580 and KH550, the mass ratio is 4-7:2-4, the temperature of the heating and stirring reaction is 40-50°C, and the time is 2-4h.
6. The preparation method according to claim 2, characterized in that: The mass ratio of coenzyme Q10 to valproic acid in step S4 is 5-7:1-2.
7. The preparation method according to claim 2, characterized in that: The mass ratio of the modified microspheres, avasimibe / polyantibiotic cocrystal, and additives in step S5 is 50:0.5-1:1-2.
8. The preparation method according to claim 2, characterized in that: The specific steps include: S1. Preparation of Avasimibe / Polyantigen A cocrystal: Dissolve Avasimibe in DMSO solvent to obtain solution A, wherein the solid-liquid ratio of Avasimibe to DMSO solvent is 3-4:100 g / mL; Dissolve Polyantigen A in water to obtain solution B, wherein the solid-liquid ratio of Polyantigen A to water is 7-10:100 g / mL; Mix 10 parts by weight of solution A and 25-32 parts by weight of solution B, evaporate the solvent in an open manner, filter, wash, dry, and ball-mill for 1-3 hours to obtain Avasimibe / Polyantigen A cocrystal; S2. Preparation of porous microspheres: 7-10 parts by weight of alkyl orthosilicate was dissolved in ethanol, dropped into 100 parts by weight of an aqueous solution containing ammonia and a porogen, stirred for 12-15h, centrifuged, washed, and dried to obtain porous microspheres; In the aqueous solution containing ammonia water and a porogen, the mass ratio of ammonia water, the porogen and water is 5-7:2-3:30-50; S3. Preparation of modified microspheres: 15-20 parts by weight of the porous microspheres prepared in step S2 were added to ethanol, 4-7 parts by weight of a composite silane coupling agent and 2-4 parts by weight of tannic acid were added, heated to 40-50 ° C, stirred for 2-4h, centrifuged, washed, and dried to obtain modified microspheres; The composite silane coupling agent is KH580 and KH550, with a mass ratio of 4-7:2-4; S4. Preparation of additives: 5-7 parts by weight of coenzyme Q10 and 1-2 parts by weight of valproic acid are mixed to obtain an additive; S5. Preparation of a composition for improving the function of CAR-T cells: add 50 parts by weight of the modified microspheres prepared in step S3 to 200 parts by weight of water, add 0.5-1 parts by weight of the avasimibe / polyantigen methyl cocrystal prepared in step S1 and 1-2 parts by weight of the additive prepared in step S4, stir and mix evenly, evaporate the solvent, wash, and dry to obtain a composition for improving the function of CAR-T cells.
9. A composition for improving CAR-T cell function obtained by the preparation method according to any one of claims 1 to 8.
10. A composition for improving CAR-T cell function as claimed in claim 9, added to a CAR-T cell culture medium, for improving CAR-T cell viability, proliferation ability and anti-tumor function.
